Literature DB >> 7679689

Stimulation of protein tyrosine phosphorylation in human B cells after ligation of the beta 1 integrin VLA-4.

A S Freedman1, K Rhynhart, Y Nojima, J Svahn, L Eliseo, C D Benjamin, C Morimoto, E Vivier.   

Abstract

B lymphocytes express several adhesion molecules that are involved in cell-cell and cell-extracellular matrix interactions. The alpha 4 beta 1 integrin VLA-4, expressed on pre-B and mature/activated B cells, mediates adhesion of these cells to its two ligands, VCAM-1 and fibronectin. Recent evidence suggests that VLA-4 is involved in T lymphocyte activation; however, relatively little is known of the role of VLA-4 in B cell differentiation. To begin to assess the potential involvement of VLA-4 in B cell activation, we have examined the effect of ligation of VLA-4 on protein tyrosine phosphorylation in B cells. We found that cross-linking of VLA-4 by either mAb or natural ligands (i.e., VCAM-1 and the FN-40 cleavage fragment of fibronectin) induced the tyrosine phosphorylation of a 110-kDa protein in a human pre-B cell line (Nalm-6), an EBV-transformed B cell line (SB), and normal tonsillar B cells. These findings suggest that VLA-4 can activate a tyrosine kinase in B cells and B cell lines. These signals may be involved in the subsequent differentiation of pre-B and mature B cells within specific microenvironments where VLA-4 mediated adhesion is operational.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7679689

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  B cell receptor-induced phosphorylation of Pyk2 and focal adhesion kinase involves integrins and the Rap GTPases and is required for B cell spreading.

Authors:  Kathy W K Tse; May Dang-Lawson; Rosaline L Lee; Doris Vong; Anica Bulic; Leonard Buckbinder; Michael R Gold
Journal:  J Biol Chem       Date:  2009-06-26       Impact factor: 5.157

Review 2.  The pathophysiologic role of alpha 4 integrins in vivo.

Authors:  R R Lobb; M E Hemler
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

Review 3.  The vitronectin receptor (alpha V beta 3) as an example for the role of integrins in T lymphocyte stimulation.

Authors:  M J Halvorson; J E Coligan; K Sturmhöfel
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

4.  Activation of complement receptor 3 on human monocytes by cross-linking of very-late antigen-5 is mediated via protein tyrosine kinases.

Authors:  B M van den Berg; R van Furth; W L Hazenbos
Journal:  Immunology       Date:  1999-10       Impact factor: 7.397

Review 5.  Mucosal addressin cell adhesion molecule-1 (MAdCAM-1). Its binding motif for alpha 4 beta 7 and role in experimental colitis.

Authors:  S Fong; S Jones; M E Renz; H H Chiu; A M Ryan; L G Presta; D Jackson
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

6.  Specialized functional properties of the integrin alpha 4 cytoplasmic domain.

Authors:  P D Kassner; R Alon; T A Springer; M E Hemler
Journal:  Mol Biol Cell       Date:  1995-06       Impact factor: 4.138

Review 7.  Molecular analysis of the physiological and pathophysiological role of alpha 4-integrins.

Authors:  G Kilger; B Holzmann
Journal:  J Mol Med (Berl)       Date:  1995-07       Impact factor: 4.599

8.  Alteration of glomerular permeability to macromolecules induced by cross-linking of beta 1 integrin receptors.

Authors:  S Adler; R Sharma; V J Savin; R Abbi; B Eng
Journal:  Am J Pathol       Date:  1996-09       Impact factor: 4.307

9.  Tyrosine Phosphorylation of a ~30 kD Protein Precedes avb3 Integrin-signaled Endothelial Cell Spreading and Motility on Matrix Proteins.

Authors:  Dean G Tang; Clement A Diglio; Kenneth V Honn
Journal:  Pathol Oncol Res       Date:  1996       Impact factor: 3.201

10.  Binding of HIV-2 envelope glycoprotein to CD8 molecules and related chemokine production.

Authors:  H Akimoto; H Kaneko; I Sekigawa; H Hashimoto; Y Kaneko; N Yamamoto
Journal:  Immunology       Date:  1998-10       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.